UAMS Site Principal Investigator: Michael Wilson, M.D., Ph.D., FAAEM, FACEP, Assistant Professor, Division of Research and Evidence-Based Medicine, UAMS College of Medicine Department of Emergency Medicine and Department of Psychiatry.
Summary: Meth-OD: a multi-site phase 2 clinical trial of IXT-m200, an anti-methamphetamine antibody that will be given to participants with acute methamphetamine toxicity at the UAMS Emergency Department.
Significance: Methamphetamine use is the No. 1 cause of drug-related deaths in Arkansas, and there are no effective FDA-approved treatments. IXT-m200 has shown in animal studies that it can significantly curb the harmful effects of methamphetamine.
TRI Services: Budget development, Medicare coverage analysis, regulatory and research nurse coordinator services.
Sponsor: InterveXion Therapeutics
Note: The foundational research behind IXT-m200 was conducted at UAMS by W. Brooks Gentry, M.D., a professor in the College of Medicine Department of Anesthesiology and Department of Pharmacology and Toxicology; and Mike Owens, Ph.D., now former professor in the Department of Pharmacology and Toxicology.